Cephalon Expects To Launch Modafinil For ADHD In Early 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
The company must resolve final Sparlon labeling issues identified in an “approvable” letter.
You may also be interested in...
Sparlon Risk Management Plan For Serious Skin Reactions To Be Discussed By Committee
During review, FDA staff disagrees about significance and implications of serious skin reactions and other adverse events with Sparlon.
Sparlon Risk Management Plan For Serious Skin Reactions To Be Discussed By Committee
During review, FDA staff disagrees about significance and implications of serious skin reactions and other adverse events with Sparlon.
Cephalon Looks To Q2 For Launch Of Sparlon
Cephalon has pushed back the anticipated launch of its attention deficit/ hyperactivity disorder drug Sparlon (modafinil) from Q1 until the second quarter, pending the outcome of a review by FDA's Psychopharmacologic Drugs Advisory Committee March 23